MDS

Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.

Post-transplant cyclophosphamide decreased the risk of complications in patients with blood cancers who underwent a stem cell transplant from an unrelated donor.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

I must admit when people call us cancer survivors "strong," it's a double-edged sword.

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.

Jakafi plus Rezurock showed promise in treating graft-versus-host disease in patients who underwent undergone allogeneic hematopoietic cell transplantation.

A cancer survivor described the agony of making a life-or-death decision.

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

A phase 2a trial administered the novel drug HT-6184 to its first patient with lower-risk myelodysplastic syndromes.

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

The FDA recently approved Tibsovo for relapsed/refractory MDS with an IDH1 mutation, a treatment option for a disease subset with no options before this approval.

My visits to the local cancer center were very impactful as a cancer survivor, and I consider that staff a part of my family.